GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as ...

GSK (NYSE:GSK) announced Thursday that the U.S. FDA has further broadened the label for its asthma therapy, approving the ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Tinder CEO Faye Iosotaluno said on Thursday that she would step down in July, as the dating app aims to attract more users.

Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard ...

GSK’s (LSE: GSK) biologic therapy Nucala (mepolizumab) has demonstrated a consistent reduction in exacerbation rates among ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

Thoughts of suicide was confirmed as a side effect of finasteride (Propecia, Proscar), the European Medicines Agency (EMA) ...

The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action ...